Department of Pharmacology, Faculty of Medicine, Minia University, Egypt.
Life Sci. 2013 Feb 7;92(2):114-8. doi: 10.1016/j.lfs.2012.11.004. Epub 2012 Nov 15.
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury worldwide. It covers a wide spectrum of hepatic disorders ranging from simple steatosis, through steatohepatitis (steatosis with inflammation), to cirrhosis. The molecular and cellular mechanisms underlying hepatic injury in NAFLD are not clear. Several evidences suggest that multiple mechanisms including insulin resistance, oxidative stress, inflammation, and genetic factors interact to initiate the development of NAFLD. Despite that there is currently no approved drug therapy for NAFLD, many approaches appear to be beneficial. Insulin sensitizers, antioxidants and antiinflammatory agents showed promising effects. This review highlights the current as well as the potential therapies of NAFLD.
非酒精性脂肪性肝病（NAFLD）是全球范围内最常见的慢性肝损伤原因。它涵盖了广泛的肝脏疾病谱，从单纯性脂肪变性，到脂肪性肝炎（脂肪变性伴炎症），再到肝硬化。NAFLD 中肝损伤的分子和细胞机制尚不清楚。有几项证据表明，包括胰岛素抵抗、氧化应激、炎症和遗传因素在内的多种机制相互作用，引发了 NAFLD 的发生发展。尽管目前尚无批准用于治疗 NAFLD 的药物，但许多方法似乎都有益处。胰岛素增敏剂、抗氧化剂和抗炎药显示出了有前景的效果。本综述重点介绍了 NAFLD 的现有和潜在疗法。
